Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure

Table 1 Clinical features of patients at the time of diagnosis

Case	Age/sex (yr)	TBil (mg/dL)	PTA	ALT (IU/L)	ALP (IU/L)	Creatinine (mg/dL)	MELD	Liver cirrhosis	HE	SIRS	Liver failure type
1	36/F	13.9	28%	300	185	0.77	22	Yes	No	No	ACLF
2	50/F	10.1	27%	326	107	0.63	29	Yes	No	No	ACLF
3	66/F	21.3	12%	452	275	0.77	30	Yes	No	Yes	ACLF
4	48/F	26.6	38%	374	158	1.37	27	Yes	No	No	ACLF
5	44/F	21.7	32%	280	134	0.83	32	No	Yes	No	Subacute
6	42/M	32.8	39%	791	144	1.32	31	No	Yes	Yes	Subacute
7	33/F	29.0	30%	139	148	0.93	24	No	No	No	Subacute
8	19/F	15.6	33%	234	439	2.87	36	Yes	No	Yes	ACLF
9	67/M	25.5	19%	145	54	0.87	29	Yes	Yes	No	ACLF
10	58/F	27.9	36%	274	212	1.23	30	No	Yes	No	Subacute
11	59/F	24.0	20%	138	150	1.50	41	Yes	No	No	ACLF
12	75/F	19.6	30%	725	173	0.86	23	Yes	No	No	ACLF
13	56/F	29.8	31%	268	420	0.80	31	No	Yes	No	Subacute
14	41/F	32.5	5%	99	81	1.87	44	Yes	Yes	No	ACLF
15	72/M	27.4	19%	400	195	1.54	38	No	Yes	No	Acute
16	45/F	11.1	39%	512	162	0.58	22	Yes	No	No	ACLF
17	45/F	19.0	38%	557	290	0.87	22	No	No	No	Subacute
18	39/F	23.0	26%	147	35	0.75	21	Yes	Yes	No	ACLF
19	72/F	23.3	23%	337	123	1.41	36	Yes	Yes	No	ACLF
20	52/F	17.1	38%	197	168	0.76	19	No	No	No	Subacute
21	65/F	17.7	35%	134	32	0.66	19	No	No	Yes	Subacute
22	40/F	27.1	31%	76	92	1.67	31	Yes	No	No	ACLF

HE: Hepatic encephalopathy; SIRS: Systemic inflammatory response syndrome; TBil: Total bilirubin; PTA: Prothrombin activity; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; MELD: Model for end-stage liver disease; ACLF: Acute on chronic liver failure.